Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
तुलना करने के लिए मीट्रिक्स | IVA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIVAपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −2.1x | −2.4x | −0.5x | |
PEG अनुपात | 0.08 | 0.02 | 0.00 | |
क़ीमत/बुक | −3.6x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 27.5x | 4.2x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 204.0% | 180.8% | 52.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.6% | 8.7% | अनलॉक करें |